Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ESR1 | P03372 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
| ▸ | TYR | P14679 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL79980 | 0.80 | ESR2 (0.52) | ESR2MEN1KMT2AESR1LMNA | |
| SCHEMBL1274301 | 0.78 | CYP1A2 (0.50) | ESR2MEN1KMT2AESR1HIF1A | |
| SCHEMBL1277361 | 0.76 | APP (0.42) | ESR2MEN1KMT2AESR1LMNA | |
| SCHEMBL1191086 | 0.71 | ESR2 (0.65) | ESR2MEN1KMT2AESR1LMNA | |
| SCHEMBL18198 | 0.71 | ESR2 (1.00) | ESR2MEN1KMT2AESR1LMNA | |
| SCHEMBL249169 | 0.71 | ESR2 (1.00) | ESR2MEN1KMT2AESR1LMNA | |
| SCHEMBL7811939 | 0.71 | ESR2 (1.00) | ESR2MEN1KMT2AESR1LMNA | |
| SCHEMBL3175106 | 0.71 | ESR2 (1.00) | ESR2MEN1KMT2AESR1LMNA | |
| SCHEMBL201046 | 0.71 | ALDH1A1 (0.55) | MEN1KMT2ANPC1ALDH1A1CYP3A4 | |
| SCHEMBL2049674 | 0.71 | APP (0.42) | CA1CA2CYP3A4CA9LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 760 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024212137-A1 | CRYSTALLINE FORMS OF A 1H-1, 2, 3-TRIAZOLE-4-CARBOXYLIC ACID COMPOUND | Cantero Therapeutics, Inc. (US) | 2024-10-17 | — | — | WO | claimed |
| US-20190076552-A1 | Precursor of a histone deacetylase inhibitor PET imaging compound for tracking cerebral neurodegenerative and tumor diseases | INSTITUTE OF NUCLEAR ENERGY RESEARCH, NUCLEAR ENERGY COUNCIL, EXECUTIVE YUAN (TW) | 2019-03-14 | — | — | US | claimed |
| US-9919995-B2 | Photoactivatable caged compounds with AIE characteristics: method of preparation and applications | Tang, Benzhong (CN) | 2018-03-20 | — | — | US | claimed |
| US-20150376112-A1 | Photoactivatable Caged Compounds with AIE Characteristics: Method of Preparation and Applications | TANG, BENZHONG (HK) | 2015-12-31 | — | — | US | claimed |
| CN-122055371-A | Faster automated iterative C-C bond formation | 伊利诺伊大学评议会 | 2026-05-15 | — | — | CN | disclosed |
| WO-2026102327-A1 | METHODS FOR COVALENTLY FUNCTIONALIZING SEMICONDUCTING SINGLE WALLED CARBON NANOTUBES AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2026-05-15 | — | — | WO | disclosed |
| US-12624032-B2 | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | UNIVERSITY OF HOUSTON SYSTEM (US) | 2026-05-12 | — | — | US | disclosed |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260070905-A1 | Derivatives of Imidazo[1,2-A]Pyridine with Anti-Inflammatory Activity | UNIV DE VELENCIA (ES) | 2026-03-12 | — | — | US | disclosed |
| EP-4695242-A1 | NOVEL SUBSTITUTED PYRROLE COMPOUNDS, COMPOSITIONS COMPRISING THE SUBSTITUTED PYRROLE COMPOUND, AND METHODS OF USE THEREOF | Meta Pharmaceuticals (HK) Limited (HK) | 2026-02-18 | — | — | EP | disclosed |
| US-12552809-B2 | Compound for organic electric element, organic electric element comprising the same, and electronic device thereof | DUK SAN NEOLUX CO., LTD. (KR) | 2026-02-17 | — | — | US | disclosed |
| US-6307056-B1 | INHIBIT OR MODULATE PROTEIN KINASES, IN PARTICULAR JNK PROTEIN KINASES. | HOFFMAN-LA ROCHE INC. | 2001-10-23 | — | — | US | disclosed |
| WO-2001040217-A1 | NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | PFIZER PRODUCTS INC. (US) | 2001-06-07 | — | — | WO | disclosed |
| WO-2000035909-A1 | 4-ARYLOXINDOLES AS INHIBITORS OF JNK PROTEIN KINASES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-22 | — | — | WO | disclosed |
| EP-0758243-A4 | BINDING OF E-SELECTIN, P-SELECTIN OR L-SELECTIN TO SIALYL-LEWISx OR SIALYL-LEWISa | TEXAS BIOTECHNOLOGY CORP (US) | 1997-08-20 | — | — | EP | disclosed |
| US-5622937-A | Compositions and methods of inhibiting the binding of E-selectin or P-selectin or sialyl-Lewisx or sialyl-Lewisa | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1997-04-22 | — | — | US | disclosed |
| EP-0758243-A1 | BINDING OF E-SELECTIN, P-SELECTIN OR L-SELECTIN TO SIALYL-LEWISx OR SIALYL-LEWISa | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1997-02-19 | — | — | EP | disclosed |
| WO-1995029682-A1 | BINDING OF E-SELECTIN, P-SELECTIN OR L-SELECTIN TO SIALYL-LEWISx OR SIALYL-LEWIS?a¿ | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1995-11-09 | — | — | WO | disclosed |
| WO-1995029681-A1 | COMPOSITIONS AND METHODS FOR INHIBITING THE BINDING OF E-SELECTIN OR P-SELECTIN TO SIALYL-LEWISx OR SIALYL-LEWIS?a¿ | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1995-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | ESR2 376/4885MEN1 2648/4885KMT2A 2907/4885 |
| US-20150376112-A1 | Photoactivatable Caged Compounds with AIE Characteristics: Method of Preparation and Applications | TYR, S100A9, CENPE | ESR2 2726/4885MEN1 3821/4885KMT2A 3189/4885 |
| US-20190076552-A1 | Precursor of a histone deacetylase inhibitor PET imaging compound for tracking cerebral neurodegenerative and tumor diseases | H1-3, H1-2, HDAC2 | ESR2 3322/4885MEN1 164/4885KMT2A 69/4885 |
| US-12624032-B2 | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | RIPK2, RIPK1, RIPK4 | ESR2 907/4885MEN1 2758/4885KMT2A 2330/4885 |
| US-20260070905-A1 | Derivatives of Imidazo[1,2-A]Pyridine with Anti-Inflammatory Activity | IL1A, IL6, IL1B | ESR2 725/4885MEN1 4831/4885KMT2A 3689/4885 |
| US-12552809-B2 | Compound for organic electric element, organic electric element comprising the same, and electronic device thereof | KCNE1, KCNN4, RER1 | ESR2 5/4885MEN1 3868/4885KMT2A 1652/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | ESR2 182/4885MEN1 1978/4885KMT2A 3362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.